share_log

In8bio | UPLOAD: Others

SEC announcement ·  Jan 16 12:28
Summary by Moomoo AI
In8bio, Inc., a biotechnology company, has been informed by the United States Securities and Exchange Commission (SEC) that its registration statement on Form S-3, filed on January 12, 2024, will not undergo review by the agency. The SEC's communication, dated January 16, 2024, was addressed to William Ho, President and CEO of In8bio. The SEC's letter reminded the company of its responsibility for the accuracy and adequacy of its disclosures, irrespective of the SEC's review process. The SEC also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Daniel Crawford from the SEC's Division of Corporation Finance, Office of Life Sciences, is the point of contact for any further inquiries from In8bio.
In8bio, Inc., a biotechnology company, has been informed by the United States Securities and Exchange Commission (SEC) that its registration statement on Form S-3, filed on January 12, 2024, will not undergo review by the agency. The SEC's communication, dated January 16, 2024, was addressed to William Ho, President and CEO of In8bio. The SEC's letter reminded the company of its responsibility for the accuracy and adequacy of its disclosures, irrespective of the SEC's review process. The SEC also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Daniel Crawford from the SEC's Division of Corporation Finance, Office of Life Sciences, is the point of contact for any further inquiries from In8bio.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more